Drug Trial Radar · NCT05902598
A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Jul 10, 2023
Primary completion
Nov 26, 2024
Study completion Jan 9, 2026
Sponsor
- Lead sponsor
- Visirna Therapeutics HK LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Arrowhead Pharmaceuticals
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo controlled, two periods phase 3 clinical study. The primary objective of the study was to evaluate the efficacy and safety of Plozasiran injection in Chinese adults with familial chylomicronemia syndrome (FCS). A total of 37 participants were enrolled in the study. The duration of the study randomized period was approximately 112 weeks, including a screening period of up to 8 weeks and a treatment period of up to 104 weeks. Participants who completed the randomized period will continue in a 1-year open-label extension period where all participants will receive Plozasiran.
Conditions
- Familial Chylomicronemia Syndrome
Interventions
PlozasiranDrug
Subcutaneous injection
PlacebonDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10Time frame: Baseline to Month 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.